Oncomed Pharmaceuticals, Inc.

Dyax Corporation

Twist Bioscience Corporation

Bracco Suisse Sa

Sutro Biopharma, Inc.

Surrozen Operating, Inc.

Celgene Corporation

Bracco International Bv

Syntonix Pharmaceuticals, Inc.

Collagen Medical, LLC

Mereo Biopharma 5, Inc.

Biogen Hemophilia Inc.

Takeda Pharmaceutical Company Limited

Bioverativ Therapeutics Inc.

Aaron Sato

Austin L Gurney

Daniel T Dransfield

Timothy Charles Hoey

Palaniappa Nanjappan

Robert Charles Ladner

Fumiko Takada Axelrod

Qiang Liu

Rolf E Swenson

Kondareddiar Ramalingam

Adrian D Nunn

Karen E Linder

Edmund R Marinelli

Radhakrishna K Pillai

Bo Song

Mathew A Von Wronski

Hong Fan

Ajay Shrivastava

Philippe Bussat

Ryan Stafford

Christophe Arbogast

Sharon Michele Walker

Christopher John Bond

Sibylle Pochon

Edward Thein Htun Van Der Horst

Yang Li

John A Lewicki

Sanjeev Satyal

Wen-Chen Yeh

Alice Yam

Maureen Fitch Bruhns

Satyajit Sujit Kumar Mitra

Yuan Ching Liu

Tom Yuan

Pankaj Garg

Feng Yan

Junhao Yang

Tom Zhiye Yuan

Maureen Fitch-Bruhns

John Lee

Alan J Bitonti

Daniel J Sexton

Clive R Wood

Kevin McDonnell

Jennifer A Dumont

Christopher TenHoor

Avinash Gill

Arumugam Muruganandam

Claudia Yvonne Janda

Ray Tabibiazar

Chenggang Lu

Linya Wang

Liming Liu

Arthur Charles Ley

Vincent Jacques

Malini Viswanathan

Peter Caravan

Andrew Kolodziej

Richard J Looby

Stephane A Dumas

Randall J Brezski

Kalyani Penta

Xiaofan Li

Zhaoda Zhang

Helene Baribault

Aida Abujoub

Sudha Khurana

James Stattel

Charles R Wescott

Kuo-Pao Lai

Alexandra Lazetic

Steffi K Koerner

Wei-Chuan Sun

Parthasarathy Sampathkumar

Tristan William Fowler

Zhimin Ji

Biplab Kumar Das

David R Buckler

Christopher D Thanos

Edward Hirsch Cohen

Heather Stephenson

James P Beltzer

Zhengjian Zhang

James McGivney

Stephanie Armstrong

Mark Stochl

Sybille Pochon

Liqin Xie

Mary Mathieu

Jennifer Jean Brady

Teppei Yamaguchi

Jennifer Dumont

Christopher Tenhoor

Clive Wood

Kevin Mcdonnell

Provided herein are methods and compositions relating to glucagon-like peptide-1 receptor (GLP1R) libraries having nucleic acids encoding for immunoglobulins that bind to GLP1R. Libraries described herein include variegated libraries comprising nucleic acids each encoding for a predetermined variant of at least one predetermined reference nucleic acid sequence. Further described herein are protein libraries generated when the nucleic acid libraries are translated. Further described herein are cell libraries expressing variegated nucleic acid libraries described herein.

Methods and compositions relating to GLP1R variants

Provided herein are methods and compositions relating to glucagon-like peptide-1 receptor (GLP1R) libraries having nucleic acids encoding for a scaffold comprising a GLP1R binding domain. Libraries described herein include variegated libraries comprising nucleic acids each encoding for a predetermined variant of at least one predetermined reference nucleic acid sequence. Further described herein are protein libraries generated when the nucleic acid libraries are translated. Further described herein are cell libraries expressing variegated nucleic acid libraries described herein.

Antibodies that bind GLP1R

Provided herein are methods and compositions relating to improved bispecific antibodies capable of binding and neutralizing SARS-CoV-2 variants.

Bispecific SARS-CoV-2 antibodies and methods of use

Provided herein are methods and compositions relating to libraries of optimized antibodies having nucleic acids encoding for an antibody comprising modified sequences. Libraries described herein comprise nucleic acids encoding SARS-CoV-2 or ACE2 antibodies. Further described herein are protein libraries generated when the nucleic acid libraries are translated. Further described herein are cell libraries expressing variegated nucleic acid libraries described herein.

Variant nucleic acid libraries for coronavirus

The present invention provides Wnt pathway agonists and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of diseases.

Wnt surrogate molecules and uses thereof

Provided herein are methods and compositions relating to CD3 libraries having nucleic acids encoding for a scaffold comprising a CD3 domain. CD3 libraries described herein encode for immunoglobulins such as antibodies.

Antibodies that bind CD3 Epsilon

Provided herein are methods and compositions relating to adenosine A2A receptor libraries having nucleic acids encoding for a scaffold comprising an adenosine A2A binding domain. adenosine A2A receptor libraries described herein encode for immunoglobulins such as antibodies.

Methods and compositions relating to adenosine receptors

Methods and compositions relating to covid antibody epitopes

Provided herein are methods and compositions relating to variant nucleic acid libraries encoding for antibodies including single domain antibodies. Libraries generated using methods described herein have improved characteristics including improved binding affinity. Libraries described herein include variegated libraries comprising nucleic acids each encoding for a predetermined variant of at least one predetermined reference nucleic acid sequence. Further described herein are protein libraries generated when the nucleic acid libraries are translated. Further described herein are cell libraries expressing variegated nucleic acid libraries described herein.

Antibodies that bind CD3 epsilon

Provided herein are methods and compositions relating to libraries of optimized antibodies having nucleic acids encoding for an antibody comprising modified sequences. Libraries described herein comprise nucleic acids encoding Dickkopf WNT signaling pathway inhibitor 1 (DKK1) antibodies. Further described herein are protein libraries generated when the nucleic acid libraries are translated. Further described herein are cell libraries expressing variegated nucleic acid libraries described herein.

Dickkopf-1 variant antibodies and methods of use

Provided herein are methods and compositions relating to prostaglandin D2 receptor 2 (DP2 or CRTH2R) libraries having nucleic acids encoding for a scaffold comprising a CRTH2R binding domain. CRTH2R libraries described herein encode for immunoglobulins including antibodies and single domain antibodies. Libraries described herein include variegated libraries comprising nucleic acids each encoding for a predetermined variant of at least one predetermined reference nucleic acid sequence. Further described herein are protein libraries generated when the nucleic acid libraries are translated. Further described herein are cell libraries expressing variegated nucleic acid libraries described herein.

Variant nucleic acid libraries for CRTH2

The present invention provides anti-Fzd monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of diseases.

Anti-frizzled antibodies and methods of use

The present disclosure provides tissue-specific Wnt signal enhancing molecules, and related methods of using these molecules to increase Wnt signaling in targeted tissues.

Tissue-specific Wnt signal enhancing molecules and uses thereof

Provided herein are compositions, methods and uses involving antibodies that specifically bind to human CD47. Also provided are uses and methods, such as therapeutic methods, diagnostic methods, and methods of making such antibodies.

Anti-CD47 antibodies and uses thereof

Growing community of inventors

Burlingame, CA, United States of America

Aaron Sato